Renal cell carcinoma (RCC)

Disease · 3 studies in the Atlas

Cancer of the kidney; target indication for everolimus treatment in clinical practice.

Evidence at a glance

Tier	What it means	Studies
B	Direct human evidence	2
D	Mechanistic / in vitro / review	1

Studies

Study	Year	Tier	Finding
MOT2008	2008	B	Everolimus extended median progression-free survival from 1.9 to 4.0 months versus placebo in metastatic renal cell carcinoma.
HUD2007	2007	B	Temsirolimus alone extended median overall survival to 10.9 months versus 7.3 months with interferon alfa in poor-prognosis metastatic kidney cancer; rash, hyperglycemia, and hyperlipidemia were more
GUE2007	2007	D	Comprehensive review arguing mTOR signaling is commonly deregulated in human cancers, laying out the rationale for rapalog trials in oncology.

Related entities

Open in the Atlas explorer